Roche Holding AG (RHHBY)
| Market Cap | 328.20B +32.4% |
| Revenue (ttm) | 79.90B +1.5% |
| Net Income | 16.24B +55.6% |
| EPS | 20.23 +55.6% |
| Shares Out | n/a |
| PE Ratio | 20.21 |
| Forward PE | 15.76 |
| Dividend | 0.97 (1.89%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 2,066,707 |
| Open | 51.49 |
| Previous Close | 51.57 |
| Day's Range | 51.02 - 51.72 |
| 52-Week Range | 37.51 - 60.85 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 56.66 (+10.06%) |
| Earnings Date | Jul 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RHHBY stock is "Buy." The 12-month stock price target is $56.66, which is an increase of 10.06% from the latest price.
News
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial
Roche said on Friday that patients lost 22.7% of their body weight in a mid-stage trial of its dual-acting experimental obesity drug, with more than a quarter of those who received the highest dose a...
Zealand touts promising tolerability data for obesity drug in mid-stage study
Zealand Pharma said on Friday its experimental obesity drug, co-developed with Swiss partner Roche , showed encouraging tolerability in a mid-stage trial, bolstering its push to take on market leader...
Roche Develops Ebola PCR Test In Six Days Amid Bundibugyo Outbreak
(RTTNews) - Roche (RHHBY) has announced the rapid development of a Research Use Only (RUO) PCR test to detect the rare Ebola Bundibugyo virus, completing the assay within just six days of the genome s...
Roche reports developing PCR test for Ebola within six days
Roche (RHHBY) announced that it developed a Research Use Only molecular PCR test, via its subsidiary TIB MOLBIOL, for use on the LightCycler 480 I & II Systems, LightCycler PRO…
Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection
New Roche test targeting detection of Bundibugyo virus supports efforts to address critical need during ongoing outbreaks 1 Roche's unique outbreak response capabilities enabled rapid development of t...
Roche chairman likens US tariff policy to 'blackmail'
The chairman of Swiss pharmaceutical giant Roche hit out at U.S. tariff policies on Thursday, likening them to "blackmail", and said protectionism by the United States and China was the firm's bigge...
Ideaya Biosciences announces IDE892 collaboration with Roche
Ideaya Biosciences (IDYA) announced it has entered into a clinical collaboration with Roche (RHHBY) to evaluate the efficacy and safety of IDE892 in combination with Roche’s RG6505, a pan-RAS inhibito...
Roche Holding AG Transcript: Investor update
Oncology and hematology delivered strong Q1 growth, led by breast and lung cancer therapies and pipeline innovation. Giredestrant showed significant efficacy in adjuvant breast cancer, with multiple ongoing trials to expand its use. Divarasib and other RAS-targeted therapies are advancing, with a focus on combination strategies and new modalities.
Roche Holding AG Slides: Investor update
Roche Holding AG has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
FDA Grants Priority Review For Roche's NDA For Giredestrant In Breast Cancer
(RTTNews) - Roche Holding AG (RHHBY), a healthcare company, reported that its New Drug Application seeking approval for Giredestrant as an adjuvant treatment for patients with stage I-III ER+/HER- bre...
Genentech announces FDA acceptance of giredestrant NDA under Priority Review
Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s new drug application, or NDA, under Priority Review for giredestrant, an investigational oral selective estrogen...
Roche Announces FDA's Filing Acceptance Under Priority Review For Giredestrant
(RTTNews) - Roche (RHHBY, RO.SW, ROG.SW) announced the FDA has accepted the company's New Drug Application under Priority Review for giredestrant, an investigational oral selective oestrogen receptor ...
FDA Accepts New Drug Application for Genentech's Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--FDA accepts NDA for Genentech's giredestrant in ER+ early-stage breast cancer.
FDA accepts New Drug Application for Roche's giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
Basel, 02 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States (US) Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) under Prio...
Genentech Presents Updated Clinical Results Of Enicepatide And Petrelintide At ADA 2026
(RTTNews) - Genentech, a biotechnology company and member of the Roche group (RHHVF), announced that it will present new clinical data for Enicepatide and Petrelintide from its obesity portfolio to ad...
Louth GAA FL Division 2 Round-up: Walsh in sizzling form for Fechins as Roche sit top
Roche to present new data advancing its obesity portfolio at the American Diabetes Association's 2026 Scientific Sessions
Basel, 1 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that new data from its obesity portfolio will be presented at the 2026 Scientific Sessions of the American Diabetes Association®...
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association's 2026 Scientific Sessions
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that new data from its obesity portfolio will be presented at the 202...
Roche Launches Liver Disease Panel To Help Clinicians Identify Risk Earlier
(RTTNews) - Roche (RHHBY, RO.SW, ROG.SW) announced the launch of its Liver Disease Panel, a suite of certified algorithms including the CE-marked algorithm LiverPRO, to support better-informed clinica...
Louth GAA FL Div 2 Round-up: Roche remain top after seeing off O’Raghallaighs
Roche Emmets 2-19 O’Raghallaighs 1-15
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), will present new data from nine approved and investigational medicines across more th...
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
Basel, 19 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data from nine approved and investigational medicines across more than 15 indications at the 2026 American Society of Clinical ...
Roche, Medicines Patent Pool sign deal to expand access to influenza drug
Roche and the Medicines Patent Pool have signed a licensing agreement to expand access to the Swiss drugmaker's flu drug, Xofluza, in low- and middle-income countries, the organizations said on Monda...
FDA approves Genentech’s Tecentriq for adjuvant muscle-invasive bladder cancer
Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Tecentriq and Tecentriq Hybreza as an adjuvant treatment for adult patients with…
FDA Approves Genentech's Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentr...